Improved insulin adherence after introduction of a smart connected insulin pen

Niels V Hartvig1, Jakob Helldén2, Anne Kaas3, Mikkel Nygaard Knudsen4, Ann-Charlotte Mårdby5, Jonas B Møller6, Peter Adolfsson7
1Global Development, Data Science, Novo Nordisk A/S, Søborg, Denmark; 2Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 3Medical Affairs, Novo Nordisk A/S, Malmö, Sweden; 4Digital Health, Partnerships & Commercial Strategy, Novo Nordisk A/S, Søborg, Denmark; 5The Hospital of Halden Kungaborga, Institute of Clinical Sciences University of Gøteborg, Kungaborga, Sweden

Follow-up

795

Study design

1. Global Development, Data Science, Novo Nordisk A/S, Søborg, Denmark; 2Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 3Medical Affairs, Novo Nordisk A/S, Malmö, Sweden; 4Digital Health, Partnerships & Commercial Strategy, Novo Nordisk A/S, Søborg, Denmark; 5The Hospital of Halden Kungaborga, Institute of Clinical Sciences University of Gøteborg, Kungaborga, Sweden

Methods

This was an exploratory, non-interventional study running from May 2017–Nov 2018. Twelve diabetes clinics from different parts of Sweden participated. Patients with T1D using CGM were included if they were willing to have their physician agree to their enrollment in the study. All participants received NovoPen® 6 (basal and/or bolus insulin injections). Baseline was then followed by a baseline period between pen-introduction and visit 1, during which the patients started to use the NovoPen® 6 but without access to downloads of injection data. The first data download occurred at visit 1, using GlucoXDiasend® inc. NovoPen® 6 to transfer the data from the pen to the GlucoXDiasend® user.